Form 4: Candel Therapeutics Director Aguilar-Cordova Reports Stock Sales

Director Estuardo Aguilar-Cordova and related entities report sales of Candel Therapeutics stock over three days in October.

Summary

• Estuardo Aguilar-Cordova, a director and 10% owner of Candel Therapeutics, along with related entities, reported sales of CADL stock.
• On October 1, 2024, 6,214 shares were sold at a price of $7.0091 per share.
• On October 2, 2024, 26,988 shares were sold at a price of $6.92 per share.
• On October 3, 2024, 1,800 shares were sold at a price of $6.85 per share.
• Following these transactions, Aguilar-Cordova directly owns 171,335 shares jointly with his spouse.
• Aguilar-Cordova also indirectly owns shares through the Estuardo Aguilar-Cordova 2020 Irrevocable Trust (2,074,942 shares), the Laura K. Aguilar 2020 Irrevocable Trust (2,013,100 shares), and Laura K. Aguilar (874,943 shares).

Sentiment

Score: 4

Explanation: Insider selling can create negative sentiment, but without more context, it's difficult to assess the full impact. The sales are relatively small compared to the total holdings.

Negatives

• The director's stock sales could be interpreted negatively by investors.

Risks

• Continued selling pressure from insiders could negatively impact the stock price.

Industry Context

Insider sales are a common occurrence, but investors often monitor them closely for signals about a company's prospects. Large or frequent sales can sometimes raise concerns.

Stakeholder Impact

• Shareholders may react to the news of insider selling.

Key Dates